KR20240110109A - 조합하여 사용되는 항진균제 - Google Patents

조합하여 사용되는 항진균제 Download PDF

Info

Publication number
KR20240110109A
KR20240110109A KR1020247022473A KR20247022473A KR20240110109A KR 20240110109 A KR20240110109 A KR 20240110109A KR 1020247022473 A KR1020247022473 A KR 1020247022473A KR 20247022473 A KR20247022473 A KR 20247022473A KR 20240110109 A KR20240110109 A KR 20240110109A
Authority
KR
South Korea
Prior art keywords
combination
antifungal
compound
pharmaceutically acceptable
fungal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247022473A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 에이. 안굴로 곤잘레스
Original Assignee
싸이넥시스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 싸이넥시스, 인크. filed Critical 싸이넥시스, 인크.
Publication of KR20240110109A publication Critical patent/KR20240110109A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020247022473A 2017-04-10 2018-04-04 조합하여 사용되는 항진균제 Pending KR20240110109A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762483647P 2017-04-10 2017-04-10
US62/483,647 2017-04-10
KR1020197032870A KR102683355B1 (ko) 2017-04-10 2018-04-04 조합하여 사용되는 항진균제
PCT/US2018/026088 WO2018191077A1 (en) 2017-04-10 2018-04-04 Antifungal agents used in combination

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197032870A Division KR102683355B1 (ko) 2017-04-10 2018-04-04 조합하여 사용되는 항진균제

Publications (1)

Publication Number Publication Date
KR20240110109A true KR20240110109A (ko) 2024-07-12

Family

ID=62063223

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247022473A Pending KR20240110109A (ko) 2017-04-10 2018-04-04 조합하여 사용되는 항진균제
KR1020197032870A Active KR102683355B1 (ko) 2017-04-10 2018-04-04 조합하여 사용되는 항진균제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197032870A Active KR102683355B1 (ko) 2017-04-10 2018-04-04 조합하여 사용되는 항진균제

Country Status (13)

Country Link
US (2) US11110102B2 (https=)
EP (1) EP3609539A1 (https=)
JP (2) JP7263313B2 (https=)
KR (2) KR20240110109A (https=)
CN (1) CN110769854B (https=)
AR (1) AR113221A1 (https=)
AU (1) AU2018253031B2 (https=)
CA (1) CA3059225A1 (https=)
EA (1) EA201992413A1 (https=)
MA (1) MA49889A (https=)
MX (1) MX2019012116A (https=)
TW (1) TWI806861B (https=)
WO (1) WO2018191077A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102807716B1 (ko) * 2017-08-04 2025-05-13 싸이넥시스, 인크. 산성 pH에서 증진된 활성을 갖는 항진균제
BR112021016876A2 (pt) * 2019-02-27 2021-11-03 Scynexis Inc Métodos para tratar e para prevenir pneumonia por pneumocystis, métodos para tratar e para prevenir pneumonia por pneumocystis jirovecii, preparação de um medicamento para tratar ou prevenir pneumonia por pneumocystis jirovecii, e, uso de um composto
AU2020276595B2 (en) * 2019-05-16 2025-12-04 Scynexis, Inc. Antifungal Agents for Candida Auris Decolonization

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
WO2010019204A1 (en) * 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
KR101686075B1 (ko) * 2008-08-12 2016-12-13 싸이넥시스, 인크. 항균제
CA2982660C (en) * 2014-11-21 2023-01-24 F2G Limited 2-(1,5-dimethyl-3-phenyl-1h-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazine-1-yl)phenyl)-2-oxoacetamide and derivatives thereof for use as antifungal agents
HRP20220544T1 (hr) 2015-01-19 2022-08-05 Scynexis, Inc. Nove soli i polimorfi scy-078

Also Published As

Publication number Publication date
TWI806861B (zh) 2023-07-01
TW201842915A (zh) 2018-12-16
US20220202833A1 (en) 2022-06-30
EA201992413A1 (ru) 2020-03-16
AU2018253031A1 (en) 2019-10-31
AR113221A1 (es) 2020-02-19
CA3059225A1 (en) 2018-10-18
JP7263313B2 (ja) 2023-04-24
KR102683355B1 (ko) 2024-07-10
JP2020513037A (ja) 2020-04-30
AU2018253031B2 (en) 2024-04-11
US11110102B2 (en) 2021-09-07
CN110769854B (zh) 2023-01-13
MX2019012116A (es) 2019-11-21
JP2023030113A (ja) 2023-03-07
KR20190133251A (ko) 2019-12-02
JP7574268B2 (ja) 2024-10-28
EP3609539A1 (en) 2020-02-19
CN110769854A (zh) 2020-02-07
US20180325919A1 (en) 2018-11-15
BR112019021138A2 (pt) 2020-05-12
MA49889A (fr) 2020-06-24
WO2018191077A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
JP7574268B2 (ja) 併用される抗真菌剤
US20260000656A1 (en) Antifungal agents with enhanced activity in acidic ph
EP3917534B1 (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40022879B (en) Antifungal agents used in combination
HK40022879A (en) Antifungal agents used in combination
BR112019021138B1 (pt) Combinação farmacêutica, e, uso de uma combinação farmacêutica
EA047299B1 (ru) Фармацевтическая комбинация тритерпеноидного производного энфумафунгина с изавуконазолом и ее применение для лечения инвазивного аспергиллеза легких
HK40091926A (en) Antifungal agents with enhanced activity in acidic ph
HK40030410A (en) Antifungal agents with enhanced activity in acidic ph
HK40030410B (en) Antifungal agents with enhanced activity in acidic ph
EA047126B1 (ru) Противогрибковое средство для лечения или профилактики инфекции вульвовагинального кандидоза

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000